ChemoTech’s new Center of Excellence (CoE) at the India-Sweden Healthcare Innovation Hub at AIIMS in Jodhpur, India India has progressed to initial approval for its ethics committee for head and neck cancer.
AIIMS, Jodhpur in India has received ethical approval for “A clinical applicability study of the tumor-specific electroporation technique for patients with locally advanced or recurrent head and neck cancer using IQwave 3.0 CE“.
The Investigator Initiated Trial (IIT) was presented to the Ethics Board by Principal Investigator Dr. Jeewan Ram VishnoiAssociate Professor, Department of Surgical OncologyAIIMS, Jodhpur
The trial is being conducted under the India-Sweden Healthcare Innovation Centre, a collaboration between AIIMS Delhi, AIIMS Jodhpur and Business Sweden – Swedish Trade Commissioner’s Office.
The trial will begin enrolling patients as soon as certain protocol changes have been submitted.
“Tumour-specific electroporation (TSE) is an evolving paradigm in the treatment of solid tumors with growing evidence not only for regional tumor control in a palliative care setting, but also in the first lines of treatment approaches. cure. – says Dr. Suhail Mufti, Medical Advisor for ChemoTech
“We are very excited to be about to start one of the largest clinical projects in the history of ChemoTech. Although we have so far treated hundreds of patients with different indications, we are not only at the beginning of our journey. It is after achieving success in clinical trials with competent and recognized organizations like AIIMS that our technology will come closer to becoming a contribution to standard therapy.” – said Mohan Frick CEO
This disclosure contains information that ChemoTech is required to make public under the EU Market Abuse Regulation (EU 596/2014). The information has been submitted for publication, through the contact person, the 13-07-2022 08:55 CET.
For more information please contact:
Telephone: +46 (0)10-218 93 00
Certified Advisor: Bank Erik ThinkingSuch. : +46 8 463 80 00, Email: email@example.com
Scandinavian ChemoTech AB (publication)
ChemoTech is a Swedish medical technology company based in lund which has developed a patented technology platform to provide cancer patients with access to a new treatment alternative, Tumor-Specific Electroporation™ (TSE), available for the treatment of humans and animals. There are a large number of cancer patients whose tumours, for various reasons, cannot be treated by conventional methods but for whom TSE can be a solution. Therefore, the company is constantly evaluating new opportunities and application areas for the technology. Shares of ChemoTech (CMOTEC B) are listed on the Nasdaq First North Growth Market in stockholm and Bank Erik Thinking is the company’s certified advisor. Learn more at: www.chemotech.se.
(c) Decision 2022. All rights reserved., sources Press Releases – English